Financial Results for the Fiscal Year
Ended March 31, 2022 (FY2021)

from the beginning

Financial Results for the Fiscal Year Ended March 31, 2022 (FY2021)

• Safe Harbor for Forward-Looking Statements and Use of Document

• Highlights

• P&L Results

• Adjusted Operating Profit Variance Analysis (Q4 YTD)

• Adjusted Operating Profit Variance Analysis (Q4)

• Revenue by Region

• C&V: Sales growth in all businesses with continued recovery of number of procedures in US and EU. Negative effects on 2H profit were mitigated by strong sales and positive FX impact

• TMCS: Pumps and infusion sets drove HCS. In 2H, multiple negative factors impacted profit

• TBCT: Continued demand recovery of whole blood collection. Although negative impacts on profit grew in 2H, maintained improved profit level in YTD

• FY22 Guidance: Double-digit growth in both revenue and profit

• Adjusted Operating Profit Variance Analysis (FY22 Guidance)

• Actions for Profit Improvement

• Dividend Proposal and Acquisition of the Company's Own Shares

• FY21-22 Product Pipeline and Topics

Reference

• Revenue by Segment and Region

• Quarterly Trend of Revenue and Operating Profit

• P&L (Quarterly Results)

• Operating Expenses (Quarterly Results)

• Operating Expenses (YTD and Quarterly Results)

• Adjusted Operating Profit: Adjustments

• CAPEX, Depreciation and R&D Expenses

• Cash Flows (Q4 YTD)

• Cash Flows (Q4)

• FY21 FX Impact Breakdown (Flow and Stock)

• Foreign Exchange Sensitivity

• Adjusted Operating Profit Variance Analysis (Q3 YTD)

@

Value of the Blood and Cell Technologies Business in the Terumo Growth Strategy

• Safe Harbor for Forward-Looking Statements and Use of Document

• Balanced Growth With All 3 Companies: Aspiration of GS26

• Portfolio Growth Trajectory

• Blood and Cell Technologies Business Growth Trajectory

• Characteristics of Blood and Cell Technologies Portfolio

• ‘Ambidextrous' Management: Both Exploitation and Exploration

• Expand the Apheresis Principle for New Therapy

• Market Potential of New Fields

• Innovation That Best Leverages the Core Technology of Centrifugation

• Plasma Innovation Breakthrough

• Strengthen Business Model

• Outlook: Sales and Adjusted Operating Profit

@

• Synergies with Terumo Group in Advanced Fields

• Blood and Cell Technologies Business Objectives